Souhaitez-vous accéder aux communiqués récents ?

Hofseth BioCare ASA ("HBC") has today entered into a consultancy agreement with James Berger (through his company Nevera AG). Mr. Berger is a dual British and Italian citizen currently residing in...

Reference is made to the stock exchange notice issued on 30 August 2019 regarding the Second Quarter 2019 Financial Report. The section “Declaration by the Board of Directors and CEO” is missing...

Reference is made to the subsequent offering of up to 1,500,000 new shares (the "Subsequent Offering") in Hofseth BioCare ASA, and the stock exchange notice issued on 18 September 2019 regarding the...

Hofseth BioCare ASA (HBC) is pleased to announce the grant of its patent no. 3399871; “A new method to improve enzyme hydrolysis and resultant protein flavor and bio-activity of fish offcuts”, with...

Hofseth BioCare ASA ("HBC" or the "Company") announces today that it has established a management incentive program (the "Program") with a total limit of 11,000,000 shares in the Company. The Program...

Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 ...

Reference is made to the stock exchange notice published on 2 September 2019 regarding a repair issue with gross proceeds of up to NOK 6 million directed towards eligible shareholders (the "Repair...

Reference is made to the stock exchange notice published by Hofseth BioCare ASA (the "Company" or "HBC") on 2 September 2019, regarding a repair issue with gross proceeds of up to NOK 6 million...

Reference is made to the stock exchange notice by Hofseth BioCare ASA ("HBC" or the "Company") published on 29 July 2019 regarding the successful completion of a NOK 118 million private placement (the...

Hofseth BioCare had operating revenues of NOK 12.8m (14.6m) in the second quarter of 2019. Cost of Goods Sold (CoGS) amounted to NOK 6.8m (11.8m) in the period. Operational profit (EBITDA) for the...